We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
WHEATON® Announces Acquisition of CELLine™
News

WHEATON® Announces Acquisition of CELLine™

WHEATON® Announces Acquisition of CELLine™
News

WHEATON® Announces Acquisition of CELLine™

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "WHEATON® Announces Acquisition of CELLine™"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

WHEATON has acquired the CELLine dual membrane, cell culture flasks from Wilson Wolf Manufacturing Corporation.

WHEATON has also entered into a long term strategic partnership with Wilson Wolf Manufacturing Corporation for further product development in high density cell culture devices for the production of concentrated, cell secreted products.

CELLine Flasks are known by their loyal users to be easy to implement and are trusted worldwide for small scale suspension and adherent cultures.

The CELLine dual membrane bioreactor system is designed as a humane alternative to hybridoma culture in the peritoneal cavity of mice, also known as the ascites method.

The flasks enhance small scale bio-production for antibody and protein generation.

Conventional in vivo or in vitro cell culture methods can be laborious, result in low cell density, and require significant purification.

The CELLine Flasks address these three areas of limitation in a single use, repeatable technology.

CELLine Flasks are ready-to-use and disposable, produce high cell density and high product concentration, while significantly reducing culture and processing time.

“We are excited to bring this innovative, high growth technology to WHEATON and to our customers around the world, enabling our customers’ life’s work. These products, combined with the existing WHEATON portfolio, support the advancement of antibody and protein research, development and production,” says Stephen R. Drozdow, President of WHEATON.

“We are also proud to have an ongoing partner with Wilson Wolf, for collaboration and further advancement of cell culture products,” he added.

Advertisement